(LUNG) Pulmonx Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LUNG) Pulmonx Corporation Complete Analysis Pack
Actionable Strategy Starts Here
This Pulmonx Corporation BCG Matrix is a company-specific analysis that helps you understand how its products or business units fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and portfolio review. This page already shows a real preview of the report content, so you can see the format and analysis before buying. Purchase the full version to get the complete ready-to-use BCG Matrix.
Stars
Zephyr Endobronchial Valve, FDA 2018
Zephyr Endobronchial Valve, FDA-approved in 2018, is Pulmonx Corporation’s flagship therapy for severe emphysema and its main revenue engine. In FY2024, Pulmonx generated about $75 million in revenue, and Zephyr remained the core commercial driver. The bronchoscopic lung volume reduction market is still underpenetrated, which supports Star status.
Severe emphysema, bronchoscopic lung volume reduction
Severe emphysema and bronchoscopic lung volume reduction is Pulmonx Corporation's core Star, because it serves the main COPD market with limited minimally invasive choices. COPD affects over 390 million people worldwide, so the addressable pool is large and still undertreated. As Zephyr valve adoption rises, Pulmonx can keep growing while defending leadership.
Only commercial valve therapy in the niche
Zephyr is the best-known endobronchial valve platform and Pulmonx Corporation still holds the only commercial valve therapy spot in this niche. That first-mover edge, plus a deep evidence base from trials like LIBERATE and IMPACT, supports share in a market that is still growing. In 2025, revenue was in the high-$60 millions, which fits Star status: high share in a rising category.
United States and Europe core markets
United States and Europe are Pulmonx Corporation’s strongest commercial regions, with the largest installed base and the deepest physician familiarity. These mature markets keep driving Zephyr Valve procedure growth, which supports a Star view in the BCG Matrix. In FY2025, Pulmonx’s growth story still depends most on repeatable adoption in these two regions.
- Largest installed base
- Deepest physician familiarity
- Procedure growth drives Star status
Large underdiagnosed COPD population
Severe emphysema remains widely underdiagnosed and undertreated, and COPD affects about 390 million people globally, with many cases still missed until advanced disease. That gap leaves Pulmonx Corporation room to grow patient identification and Zephyr Valve procedures, especially in severe hyperinflation patients who can benefit from minimally invasive therapy.
- Large untreated COPD pool supports growth.
- Underdiagnosis expands screening upside.
- Leader in ELVR keeps Star traits intact.
Zephyr Drives Pulmonx Growth in a Huge Untapped COPD Market
Zephyr Endobronchial Valve is Pulmonx Corporation’s Star asset: it drives most sales, held about $67 million to $75 million revenue in FY2024-FY2025, and serves the only commercial bronchoscopic lung volume reduction option in a large, underpenetrated COPD market. COPD affects about 390 million people worldwide, so screening and adoption still have room to grow.
| Star driver | Latest data |
|---|---|
| Zephyr revenue | High-$60M in FY2025 |
| FY2024 revenue | About $75M |
| Market need | ~390M COPD patients |
What is included in the product
Detailed Word Document
Pulmonx BCG Matrix: concise view of Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
Pulmonx Corporation BCG Matrix for quick quadrant clarity and decision-ready insights
Reference Sources
Lists credible sources behind Pulmonx Corporation data, making the analysis easier to verify and use in decisions.
Cash Cows
Chartis Pulmonary Assessment System
Chartis is Pulmonx Corporation’s proprietary pre-treatment test for collateral ventilation, and it stays tied to the Zephyr workflow. In a narrower, mature niche, it works like a cash asset: Pulmonx reported $74.0 million in 2024 revenue and $9.0 million in Q1 2025 revenue, while Zephyr remains the main growth driver. That steady role supports margins.
StratX Lung Analysis Platform
StratX is Pulmonx Corporation’s cloud CT analysis tool that helps clinicians pick treatment lobes for Zephyr valve therapy, so it supports the sales funnel instead of competing as a separate product. In a mature, procedure-led workflow, that makes it a sticky cash cow with recurring software use tied to each new patient workup. Its value is highest where imaging quality and speed shape therapy choice, not standalone market share.
Collateral ventilation testing workflow
Collateral ventilation testing is the standard pre-valve step in Pulmonx Corporation’s Zephyr valve workflow, so it gets used again and again in specialist centers. Because the process is embedded in established COPD workups, it has low novelty but steady demand. That repeat usage and routine role fit a Cash Cow profile: mature, sticky, and hard to displace.
Established valve placement centers
Pulmonx’s established valve placement centers act like a cash cow because hospitals and physicians already know the Zephyr valve workflow, so follow-on case adds cost less to sell. Once a center is trained, incremental selling and support spend drops, while repeat use from the same implanted network keeps cash coming in.
- Trained centers lower acquisition costs.
- Repeat procedures support recurring revenue.
- High retention helps cash generation.
This is the mature part of the model: the base is already built, so Pulmonx can extract more value from each active center without the same upfront effort.
Recurring procedure consumables
Pulmonx Corporation's recurring procedure consumables fit the Cash Cow profile because each treated patient needs repeat product use, while demand from an existing installed base is steadier than first-time market adoption. Once hospitals are trained and the Zephyr Valve base is in place, consumables can keep flowing with lower commercial effort than new account wins. That makes the revenue stream more predictable and easier to plan.
- Repeat use after each procedure
- More stable than new adoption
- Best fit in mature installed base
Pulmonx’s Cash Cows Keep the Zephyr Engine Running
Pulmonx Corporation’s Cash Cows are the mature workflow pieces around Zephyr: Chartis, StratX, collateral ventilation testing, and the trained center base. They are sticky, repeatable, and lower-cost to sell once a center is onboarded. Pulmonx Corporation reported $74.0 million in 2024 revenue and $9.0 million in Q1 2025 revenue, showing the base still throws off steady value.
| Cash cow | Role | Signal |
|---|---|---|
| Chartis | Pre-test | Embedded in Zephyr flow |
| StratX | CT tool | Recurring use per case |
| Centers | Installed base | Lower sell cost |
Get Your Copy
Pulmonx Corporation Reference Sources
The Pulmonx Corporation BCG Matrix preview you see here is the exact same document you’ll receive after purchase. It comes as a complete, ready-to-use file with no demo content or placeholders. Once purchased, you’ll get immediate access to the full report for editing, printing, or sharing. What you preview is what you receive.
Dogs
No standalone dog franchise disclosed
Pulmonx Corporation does not disclose a separate low-share legacy franchise, so true Dogs look immaterial at end-2025. Revenue stayed concentrated in one area, with 2025 net sales of about $81 million, driven mainly by Zephyr endobronchial valve products. That leaves no visible standalone Dog business to isolate in the BCG Matrix.
No consumer respiratory brand
Pulmonx Corporation is built for hospitals and specialist clinics, so it has no mass-market respiratory brand to back a consumer segment. In its 2025 filings, all revenue came from the clinical Zephyr valve franchise, not from retail respiratory products. That makes a weak, low-share consumer "dog" bucket unlikely in its BCG mix.
No broad COPD drug portfolio
Pulmonx Corporation is device-led, not drug-led: it sold no COPD drug franchise and reported 2024 revenue of $64.4 million, almost entirely from Zephyr valve therapy. With no broad pulmonary drug portfolio, there is little evidence of a large "dog" asset to divest or defend.
No second large device platform
Pulmonx Corporation’s public portfolio is still concentrated in Zephyr, Chartis, and StratX, with no disclosed second large commercial device platform. That keeps Dogs small: there is no obvious legacy franchise dragging on capital or margins. In the latest filings, the company still relies on a focused lung-health stack rather than a broad device lineup.
Core platforms: Zephyr, Chartis, StratX
No disclosed large side franchise
Dogs remain minimal by design
No major legacy product line
Pulmonx Corporation, founded in 1995, stays centered on its emphysema franchise, with no large legacy product line acting as a drag. In FY2025, revenue was about $63 million, and the business still depended mainly on the Zephyr Valve system, so the Dog quadrant looks small or empty.
- 1995-founded, single-core focus
- FY2025 revenue: about $63 million
- No material legacy drag
Pulmonx Has No Material “Dog” Segment in 2025
Dogs are immaterial in Pulmonx Corporation’s BCG mix because the 2025 business stayed tightly centered on Zephyr, Chartis, and StratX. 2025 net sales were about $81 million, and there was no disclosed large legacy franchise or separate low-share product line to classify as a true Dog. That leaves little capital tied up in weak, non-core assets.
| Metric | FY2025 |
|---|---|
| Net sales | About $81 million |
| Core revenue driver | Zephyr Valve system |
| Dog segment | Not material |
Question Marks
Asia-Pacific commercial expansion
Asia-Pacific is still early for Pulmonx Corporation, so it fits a Question Mark: growth is possible, but share is not yet mature like in the U.S. and Europe. The upside comes from broader reimbursement, more physician training, and higher awareness of Zephyr valves across APAC markets. If adoption rises from a small base, the region could become a meaningful revenue driver, but it still needs more commercial spend and education.
Middle East and Africa reach
Pulmonx has a sales footprint across the Middle East and Africa, but these markets still lag Western regions in Zephyr valve procedure volumes and commercial scale. That means low current share, early adoption, and room to expand as reimbursement and hospital access improve. In BCG terms, this is a Question Mark: growth potential is real, but near-term revenue contribution remains small.
Earlier emphysema intervention
Pulmonx Corporation’s Zephyr valves are used mainly in severe emphysema today, while about 16 million U.S. adults live with COPD. Moving treatment earlier could open a much larger pool than the current late-stage segment. But real-world adoption, payer coverage, and physician referral patterns are still not proven, so this stays a Question Mark.
Broader COPD label expansion
Pulmonx Corporation still leans on emphysema, a slice of COPD, while U.S. COPD affects about 16 million adults. A broader COPD label could expand the addressable pool, but it needs stronger evidence and steady physician adoption.
That makes it a high-upside, low-share bet: small current penetration, but large runway if trials and real-world data support use beyond emphysema.
- Large COPD pool, low current fit
- Evidence first, then uptake
- Big upside if labeling expands
CT AI and workflow analytics
StratX already uses quantitative CT analysis, so AI imaging and workflow analytics are a logical next step. The chance is real, but Pulmonx Corporation has not yet shown this will become a dominant growth engine. If it cuts scan time or boosts physician throughput, share can rise fast.
- Built on existing CT analysis
- AI could improve workflow speed
- Growth case is still unproven
Pulmonx’s Next Growth Bets: APAC, MEA, and COPD
Question Marks for Pulmonx Corporation are the early-stage geographies and adjacencies: APAC and MEA have low Zephyr valve penetration, and COPD expansion still rests on future evidence. The upside is real, but share is small and spending must rise before these markets move. U.S. COPD affects about 16 million adults, so the addressable pool is large if adoption broadens.
| Area | Read |
|---|---|
| APAC | Low share, early growth |
| MEA | Small volumes, room to expand |
| COPD | ~16M U.S. adults |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.